• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.

    5/15/25 4:31:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TERN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Terns Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    880881107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    880881107


    1Names of Reporting Persons

    Schonfeld Strategic Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,305,204.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,305,204.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,305,204.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.93 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The percentage of the issuer's common stock beneficially owned by the reporting person reflects 87,297,629 shares of common stock outstanding as of May 2, 2025, as set forth in the Quarterly Report on Form 10-Q filed by the issuer with the Securities and Exchange Commission on May 8, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Terns Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    1065 East Hillsdale Blvd., Suite 100, Foster City, CA 94404
    Item 2. 
    (a)Name of person filing:

    Schonfeld Strategic Advisors LLC ("Schonfeld") is an investment adviser to several private funds. Schonfeld also engages third party sub-advisers to manage assets of its private funds as separately managed accounts (the "Schonfeld SMAs"). Accordingly, Schonfeld may be deemed to indirectly beneficially own securities owned by the Schonfeld SMAs. Each Schonfeld SMA is the record and direct beneficial owner of a portion of the securities covered by this statement. Schonfeld declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934 or any other purpose, the beneficial owner of any securities covered by this statement.
    (b)Address or principal business office or, if none, residence:

    590 Madison Avenue, 23rd Floor, New York, New York 10022
    (c)Citizenship:

    Delaware limited liability company
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    880881107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,305,204 shares
    (b)Percent of class:

    4.93%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    4,305,204 shares

     (ii) Shared power to vote or to direct the vote:

    0 shares

     (iii) Sole power to dispose or to direct the disposition of:

    4,305,204 shares

     (iv) Shared power to dispose or to direct the disposition of:

    0 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities held by each of the Schonfeld SMAs as to which this statement is filed are owned of record by clients of Schonfeld. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Schonfeld Strategic Advisors LLC
     
    Signature:/s/ Hung Luc
    Name/Title:Hung Luc, Chief Compliance Officer
    Date:05/15/2025
    Get the next $TERN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TERN

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    10/31/2024$82.00Outperform
    Oppenheimer
    6/22/2023$16.00Buy
    Mizuho
    6/7/2023$18.00Buy
    Jefferies
    5/31/2023$23.00Buy
    ROTH MKM
    5/8/2023$18.00Outperform
    BMO Capital Markets
    2/14/2023$17.00Mkt Outperform
    JMP Securities
    2/7/2023$19.00Buy
    UBS
    More analyst ratings

    $TERN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

      FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June. Jefferies Global Healthcare Conference Format: Fireside Chat         Date and Time: Thursday, June 5, 2025 at 11:05 a.m ET Location: New York City Goldman Sachs 46th Annual Global Healthcare Conference Format: Fireside Chat Date and Time: Monday, June 9, 2025 at 4:00 p.m. ET

      5/29/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

      Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib Additional safety and efficacy data from CARDINAL, including 6-month major molecular response (MMR) rates expected 4Q 2025 FOSTER CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company deve

      5/14/25 9:30:00 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the first quarter ended March 31, 2025, and provided corporate updates. "Terns had a strong start to

      5/8/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Terns Pharmaceuticals Inc.

      EFFECT - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

      5/27/25 12:15:08 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.

      SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

      5/15/25 4:31:26 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Terns Pharmaceuticals Inc.

      S-3 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

      5/8/25 4:42:52 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TERN
    Leadership Updates

    Live Leadership Updates

    See more

    $TERN
    Financials

    Live finance-specific insights

    See more

    $TERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • William Blair initiated coverage on Terns Pharmaceuticals

      William Blair initiated coverage of Terns Pharmaceuticals with a rating of Mkt Perform

      2/28/25 7:33:47 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Terns Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $82.00

      10/31/24 6:27:13 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Terns Pharmaceuticals with a new price target

      Mizuho initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $16.00

      6/22/23 7:23:07 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Jung Melita Sun bought $11,498 worth of shares (2,250 units at $5.11) (SEC Form 4)

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      2/3/25 7:28:43 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Burroughs Amy L. bought $2,606 worth of shares (510 units at $5.11), increasing direct ownership by 3% to 19,609 units (SEC Form 4)

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      2/3/25 7:25:48 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Burroughs Amy L. bought $110,468 worth of shares (15,450 units at $7.15), increasing direct ownership by 423% to 19,099 units (SEC Form 4)

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      12/9/24 6:04:56 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Tripuraneni Radhika

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      6/12/25 5:44:28 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lu Hongbo

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      6/12/25 5:44:19 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kindler Jeffrey B

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      6/12/25 5:43:49 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

      FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor

      2/24/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

      FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa

      2/20/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

      FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide

      11/18/24 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

      Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, today announced positive top-line data from

      9/9/24 7:05:00 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

      TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction of 45% as assessed by MRI-PDFF with 64% of patients achieving >30% PDFF reduction All TERN-501 doses were well-tolerated with no gastrointestinal and no cardiovascular safety signals Company to host conference call and webcast at 4:30 pm ET today FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidate

      8/8/23 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

      SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

      11/15/24 10:35:07 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

      SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

      11/14/24 7:00:26 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

      SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

      11/14/24 5:51:38 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care